profit from every $100 of sales.
$0$100
Abpro Holdings
We have no price for Abpro Holdings since 19 February 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$0.01+0.00% today
-54.9% since Oct 8, 25
1-year low $0.011-year high $0.03
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Abpro Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Abpro Holdings | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Abpro Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- -0.0×
- 3.3×
- –
- –
- -1,524.9%
- -2,411.4%
- 0.0%
Profitability
- -55.2%
- -7,950.8%
- -7,670.5%
- -6,649.2%
- 93.8%
- -65.3%
- 83.2%
- -824.3%
- 93.3%
- 481.4%
Growth
- −46.3%
- –
- −21.2%
- –
- −5.5%
Financial health
- 0.0×
- -0.01
- 8.6%
- -12.3×
- 0.07
- 0.07
- 0.11
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 1%of 958
Bottom 1%of 889
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Aug 13, 2025 | -0.05 | -1.20 | +95.7% |
| Mar 31, 2025 | -0.08 | -1.20 | +93.6% |
| Dec 31, 2024 | -0.67 | – | – |
| Sep 30, 2024 | -0.04 | – | – |
| Jun 30, 2024 | -0.04 | – | – |
| Mar 31, 2024 | -0.13 | – | – |
| Dec 31, 2023 | -0.90 | – | – |
| Sep 30, 2023 | -0.00 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/6Passes 1 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
36No pass
Benjamin Graham
2No pass
Philip Fisher
40No pass
Peter Lynch
–Not enough data
Joel Greenblatt
100Pass
Charlie Munger
49No pass
Terry Smith
47No pass
Questions about Abpro Holdings
Is Abpro Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Abpro Holdings AI analysis
What does Abpro Holdings do?
Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. It is in Biotechnology.
Does Abpro Holdings pay a dividend?
No. Abpro Holdings does not pay a dividend at the moment.
Who are Abpro Holdings's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Abpro Holdings's.
Prices: daily closes to Feb 19, 2026. Fundamentals: company reports via invest-like data.